(Q45233938)

English

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

scientific article published in April 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

author name string

S S Farag

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

B J Bolwell

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

P J Elder

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M Kalaycio

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

T Lin

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

B Pohlman

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

S Penza

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

G Marcucci

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

W Blum

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

R Sobecks

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

B R Avalos

11

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

J C Byrd

12

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

E Copelan

13

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

653-661

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704867

0 references

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Etoposide in leukemia, lymphoma and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Myeloablative conditioning regimens for AML allografts: 30 years later

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

The clinical pharmacology of etoposide and teniposide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

21 January 2018

Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704867

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704867

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45233938&oldid=2070774997"